The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Adasheva T.V.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia

Samorukova E.I.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet im. A.I. Evdokimova Minzdrava Rossii;
Gorodskaia klinicheskaia bol'nitsa #11 DZ Moskvy

Zadionchenko V.S.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet im. A.I. Evdokimova Minzdrava Rossii;
Gorodskaia klinicheskaia bol'nitsa #11 DZ Moskvy

Nesterenko O.I.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet im. A.I. Evdokimova Minzdrava Rossii;
Gorodskaia klinicheskaia bol'nitsa #11 DZ Moskvy

What is the optimal choice of antihypertensive therapy based on: the class-specific effects or special properties of a drug?

Authors:

Adasheva T.V., Samorukova E.I., Zadionchenko V.S., Nesterenko O.I.

More about the authors

Journal: Therapeutic Archive. 2013;85(9): 102‑106

Read: 2792 times

Download PDF (RU)
Contact the author
Table of contents

WHAT IS THE OPTIMAL CHOICE OF ANTIHYPERTENSIVE THERAPY BASED ON: THE CLASS-SPECIFIC EFFECTS OR SPECIAL PROPERTIES OF A DRUG?
WHAT IS THE OPTIMAL CHOICE OF ANTIHYPERTENSIVE THERAPY BASED ON: THE CLASS-SPECIFIC EFFECTS OR SPECIAL PROPERTIES OF A DRUG?

To cite this article:

Adasheva TV, Samorukova EI, Zadionchenko VS, Nesterenko OI. What is the optimal choice of antihypertensive therapy based on: the class-specific effects or special properties of a drug? Therapeutic Archive. 2013;85(9):102‑106. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Predictors of Enga­gement and Active participation of Patients with Unco­ntrolled Hype­rtension in the Tele­health Surveillance Program. Russian Journal of Preventive Medi­cine. 2024;(12):37-43
Effi­cacy and tole­rability of azilsartan combined with amlo­dipine and amlo­dipine mono­therapy and combinations of amlo­dipine with other angiotensin II rece­ptor blockers. Russian Cardiology Bulletin. 2024;(4-2):161-171
Risk factors and adve­rse outcomes of cardiovascular diseases in people with high normal blood pressure of the Ryazan region. (5-year prospective follow-up). Russian Journal of Preventive Medi­cine. 2025;(2):31-37
Diagnostics of hype­rtensive diso­rders in cardio-obstetrics: current state-of-affairs. Russian Journal of Human Reproduction. 2025;(1):63-77
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Postoperative pain as a cause of hype­rtension progression in women with preeclampsia after cesa­rean section. Russian Journal of Pain. 2025;(2):83-90
Visceral obesity is a reve­rsible factor in pathogenesis of major cardiovascular diseases. Russian Cardiology Bulletin. 2025;(3):11-16
Features of the inte­rpretation of bodily sensations by patients with arte­rial hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(10):82-87
Study of the effe­ctiveness of the drug Elca­rnitine in the correction of increased variability of arte­rial pressure in patients with hype­rtensive disease and cognitive dysfunction. Russian Journal of Preventive Medi­cine. 2025;(10):88-92
Abstract:

The review article presents data on the significance of activation of different components of the renin-angiotensin-aldosterone system (RAAS) in metabolic disorder progression and organ damage processes. Based on the analysis of the pharmacological properties of drugs and clinical evidence, the authors discuss the problems of the choice of RAAS blockers. The mechanisms of drug action on metabolic processes, atherogenesis, and vascular damage are discussed.

Keywords:

renin-angiotensin-aldosterone system
angiotensin-converting enzyme inhibitors
hypertension
perindopril

Authors:

Adasheva T.V.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia

Samorukova E.I.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet im. A.I. Evdokimova Minzdrava Rossii;
Gorodskaia klinicheskaia bol'nitsa #11 DZ Moskvy

Zadionchenko V.S.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet im. A.I. Evdokimova Minzdrava Rossii;
Gorodskaia klinicheskaia bol'nitsa #11 DZ Moskvy

Nesterenko O.I.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet im. A.I. Evdokimova Minzdrava Rossii;
Gorodskaia klinicheskaia bol'nitsa #11 DZ Moskvy

Close metadata

References:

  1. Paul M.., Mehr A.P., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
  2. Dzau V.J., Bernstein K., Celermajer D. et al. For the Working Group on Tissue Angiotensin-Converting Enzyme, International Society of Cardiovascular Pharmacotherapy. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88: 1-20.
  3. Re R.N. Intracellular renin and the nature of intracrine enzymes. Hypertension 2003; 42: 117-22.
  4. Johnoston C.I., Fabris B., Yamada T. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertension 1989; 7 (5): S11-17.
  5. Vaziri N.D., Rodríguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nature Clin Pract Nephrol 2006; 2 (10): 582-593.
  6. Griengling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity incultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
  7. Sohn H.Y., Raff U., Hoffman A. et al. Differential role of angiotensin II receptor subtypes on endothelial O2-formation. Br J Pharmacol 2000; 131: 667-672.
  8. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury. Part 1: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-1916.
  9. Pepine C.J., Celermajer D.S., Drexler H. Vascular health as a therapeutic target in cardiovascular disease. University of Florida 1998; 42.
  10. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindorpil. Expert Rev Cardiovasc Ther 2005; 30: 15-29.
  11. Ceconi C., Fox K.M., Remme W.J. et al. ACE inhibition with perindopril and endothelial dysfunction: results of a substudy of the EUROPA study PERTINENT. Cardiovasc Res 2007; 73: 237-246.
  12. Rodriguez-Granillo G.A. Long-term effect of Perindopril on coronary atherosclerosis progression [from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation (PERSPECTIVE) Study]. Am J Cardiol 2007; 100: 159-163.
  13. Cangiano E., Marchesini J., Campo G. et al. ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J Cardiovasc Drugs 2011; 11: 189-198.
  14. Haier G.R., van Haeften T.W., Vesseren F.L.J. Adipose tissue disfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971.
  15. Hodge A.M., Boyko E.J., de Courten M. et al. Leptin and other component of the metabolic syndrome in Mauritius: a factor analysis. Int J Obes 2001; 25: 126-131.
  16. Engeli S., Negrel R., Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Yepertension 2000; 35 (6): 1270-1277.
  17. Nedogoda S.V. Ozhirenie i arterial'naya gipertenziya: teoriya i praktika vybora optimal'nogo antigipertenzivnogo preparata. M: Medikom 2012; 80.
  18. Nedogoda S.V., Morozova T.E. Vozmozhnosti korrektsii narushenii lipidnogo obmena ingibitorami angiotenzin-prevrashchayushchego fermenta v real'noi klinicheskoi praktike. Consilium medicum 2012; 1: 3-6.
  19. Mychka V.B., Masenko V.P., Tvorogova M.G. i dr. Primenenie perindoprila u bol'nykh myagkoi umerennoi arterial'noi gipertenziei i metabolicheskim sindromom. Arterial'naya gipertenziya 2002; 8: 36-41.
  20. Lau T., Carlsson P.O., Leung P.S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-248.
  21. Abuissa H., Jones P.G., Marso S.P., O'Keefe J.H. Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-826.
  22. Fogari R. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 316-320.
  23. Brugts J.J., Ninomiya T., Boersma E. et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPE, and PROGRESS trials. Eur Heart J 2009; 30 (11): 1385-1394.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.